Skip to main navigation Skip to search Skip to main content

Teixobactin: A Resistance-Evading Antibiotic for Treating Anthrax

  • William S. Lawrence*
  • , Jennifer E. Peel
  • , Rosan de Winter
  • , Losee L. Ling
  • , Anthony G. Nitti
  • , Aaron J. Peoples
  • , Rhythm Shukla
  • , Harold D. Macgillavry
  • , Henry S. Heine
  • , Martha E. Hensel
  • , Elbert B. Whorton
  • , Markus Weingarth
  • , Kim Lewis
  • , Dallas E. Hughes
  • *Corresponding author for this work
  • University of Texas System
  • State University System of Florida
  • Northeastern University

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The antimicrobial resistance (AMR) crisis has been associated with millions of deaths. Of particular concern is the threat of bioweapons, exemplified by anthrax. Introduction of novel antibiotics helps mitigate AMR, but does not address the threat of bioweapons with engineered resistance. We reasoned that teixobactin, an antibiotic with no detectable resistance, is uniquely suited to address the challenge of weaponized anthrax. Teixobactin binds to immutable targets, precursors of cell wall polymers. Here we show that teixobactin is highly efficacious in a rabbit model of inhalation anthrax. Inhaling spores of Bacillus anthracis causes overwhelming morbidity and mortality. Treating rabbits with teixobactin after the onset of disease rapidly eliminates the pathogen from blood and tissues, normalizes body temperature, and prevents tissue damage. Teixobactin assembles into an irreversible supramolecular structure on the surface of B. anthracis membrane, likely contributing to its unusually high potency against anthrax. Antibiotics evading resistance provide a rational solution to both AMR and engineered bioweapons.
Original languageEnglish
Pages (from-to)727-737
Number of pages11
JournalACS Infectious Diseases
Volume11
Issue number3
Early online date27 Feb 2025
DOIs
Publication statusPublished - 14 Mar 2025

Bibliographical note

Publisher Copyright:
© 2025 American Chemical Society.

Funding

The studies were funded by NIH grant R44AI152657, NIH grant R44AI118000, and DoD grant PR170869 to D.E.H. K.L. is supported by an NIH grant RO1AI170962. This project has also received funding from the European Union\u2019s Horizon Europe grant and innovation program under grant agreement no. 101045485 to M.W.. Preclinical studies offered by NIAID are gratefully acknowledged. The authors also wish to acknowledge the help and expertise of NeoSome Life Sciences, Billerica, MA, Frontage Laboratories, Inc., and the assistance of Courtney Woolsey with figure preparation. B. anthracis strains were from BEI Resources.

FundersFunder number
European Union’s Horizon Europe grant and innovation program101045485
U.S. Department of DefenseRO1AI170962, PR170869
National Institutes of HealthR44AI152657, R44AI118000

    Keywords

    • Anthrax
    • Antimicrobial resistancecrisis
    • Teixobactin

    Fingerprint

    Dive into the research topics of 'Teixobactin: A Resistance-Evading Antibiotic for Treating Anthrax'. Together they form a unique fingerprint.

    Cite this